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ABSTRACT
Activation of Platelet Activating Factor Acetylhydrolase by Proinflammatory
Mediators
by
Mohammed Abdel-al
Dr. Katherine M. Howard, Assistant Professor of Biomedical Sciences 
Dr. Ronald K. Gary, Associate Professor of Biochemistry 
Examination Committee Co-Chairs 
University of Nevada, Las Vegas
Inflammation is a highly complex and beneficial response of the host innate 
immune system often characterized by redness or swelling o f the infected area as a result 
of an injurious stimulus. The principal purpose of the inflammatory response is to rid the 
infected area of the noxious stimulus and hasten host recovery. Though the inflammatory 
response is both necessary and beneficial, if  left unregulated, it can exact a devastating 
toll on the host. Thus, an understanding of the various mediators that are able to evoke an 
inflammatory response and the signaling of these mediators is crucial. One such 
mediator, central in initiating an inflammatory response, is the biologically active 
phospholipid platelet-activating factor (PAF, l-0-alkyl-2-acetyl-.î«-glycero-3- 
phosphocholine). This phospholipid is converted to its biologically inactive form by a 
calcium-independent phospholipase A2 called PAF acetylhydrolase (PAF-AH). Thus, the 
action of PAF-AH provides a mechanism by which to hinder the propagation of an 
inflammatory response. In this study, the proinflammatory mediators, lipopolysaccharide 
(LPS), PAF, and tumor necrosis factor- a (TNF-a) were investigated for their ability to
in
upregulate PAF-AH expression. The cellular signaling pathways activated by these 
mediators were also investigated. We have demonstrated the ability of LPS, PAF, and 
TNF-a to upregulate PAF-AH levels. Further, we showed that the LPS-induced 
upregulation of PAF-AH levels is partially p38MAPK-dependent. The remaining LPS- 
induced signaling is mediated through the PAF receptor. The TNF-a and PAF-induced 
upregulation of PAF-AH levels is not p38MAPK dependent and the PAF acetylhydrolase 
induction observed may be the result of increased PAF production or signaling through 
separate pathway(s). We further demonstrate the ability of reactive oxygen species to 
induce the expression PAF acetylhydrolase.
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CHAPTER 1
INTRODUCTION 
I . I Background and Significance 
Inflammation is an elaborate, complicated, and highly integrated biological 
response of vascularized tissue to insult or injury. The principal and beneficial purpose 
of inflammation is to contain and remove offending microorganisms and necrotic tissue 
that may ensue as a result of some pathological trigger (I). While this is essential, the 
inflammatory process can also cause severe tissue injury and dysfunction via the same, 
but often accentuated, physiologic mechanisms (I). The inability to exact an 
appropriately regulated inflammatory response has led to 40 million inflammatory 
disease related cases in the United States today ranging from asthma to inflammatory 
bowel disease (2). Thus, a thorough understanding of the potent pro-inflammatory 
mediators that are essential in eliciting an inflammatory response is crucial. One such 
mediator, central in the inflammatory response, is the phospholipid platelet-activating 
factor (PAF, I-0-alkyl-2-acetyl-s'«-glycero-3-phosphocholine). The chemical structure of 
PAF is shown in Figure I (3).
H2C O CH2—(CH2)"|0—CH3
HC— O— C-CH3II
O o
H 2 C — o - - f ^ - 0 “ CH2CH2N(CH3)3 
O
Figure 1: Structure of Platelet Activating Factor. Platelet Activating Factor (PAF, 1- 
0-alkyl-2-acetyl-.s'77-glycero-3-phosphocholine) is a potent proinflammatory phospholipid 
that is central in exacting an inflammatory response. From: King, M. W. (2008) Lipid 
Metabolism. Illinois
Many isoforms of PAF exist with modifications in chain length and functionalities at 
both the sn-\ and sn-2 positions as seen in Figure 2. The most biologically potent form of 
PAF consists of a methylene chain length of sixteen carbons at the sn-\ position and an 
acetate moiety at the sn-2 position. PAF, itself, has been implicated in many 
inflammatory disease states affecting cardiovascular, gastrointestinal, pulmonary, hepatic 
and renal systems (2). PAF was originally identified through antigen stimulation o f IgE 
sensitized rabbit basophils. The phospholipid was first isolated by its ability to aggregate 
platelets and was given the name platelet-activating factor (4). The structure of PAF was 
determined by Demopoulos et al. in 1979 (5).
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Figure 2; Enzymatic action of PAF acetylhydrolase and Variations in PAF 
Structure: A. Though the inflammatory response is both necessary and beneficial, if  left 
unregulated, it can lead to the detriment of the organism. A class of enzymes categorized 
as calcium independent phospholipase A2 S called PAF acetylhydrolases help 
downregulate the inflammatory response. Upon exposure to an inflammatory agonist, 
endothelial cells are stimulated to generate PAF. PAF is then free to signal through its G- 
protein coupled receptor on various cell types of the hematpoietic cell lineage and induce 
an appropriate inflammatory response. By their action of PAF acetylhydrolases, the 
acetate moiety at the sn-2 position of PAF is cleaved generating the biologically inactive 
lyso-PAF thereby limiting the progression of the inflammatory response. B. Possible 
variations at the sn-2 position which are characteristic of PAF mimetics and are often 
induced through action of reactive oxygen species. Figure 2A is from Castro Faria Neto, 
FI. C., Stafforini, D. M., Prescott, S. M., and Zimmerman, G. A. (2005) Mem Inst 
Oswaldo Cruz 100 Suppl 1, 83-91. Figure 2B is from Tjoelker, L. W., and Stafforini, D. 
M. (2000) Biochimica Et Biophysica Acta-Molecular and Cell Biology o f  Lipids 1488, 
102-123
PAF is produced primarily by cells of the hematopoietic cell lineage and common 
sources of PAF include macrophages, monocytes, neutrophils and eosinophils (6). 
Though not part of the hematopoietic cell lineage, endothelial cells are also able to 
produce PAF (2). In cells producing PAF, the primary means of synthesis is through the 
enzymatic remodeling pathway shown in Figure 3 (1). A de novo pathway for PAF 
synthesis exists; however, this pathway is less biologically relevant. The enzymatic 
synthesis of PAF is highly regulated and involves a two step mechanism—  where the 
initial step involves the remodeling of choline containing membrane phospholipids. In 
response to inflammatory challenge, cytosolic phospholipase A: (cPLAi) associates with 
the cell membrane and hydrolyzes the esterified fatty acyl moiety at the sn-2 position 
forming lyso-PAF. Lyso-PAF becomes acetylated by an acetyltransferase to produce 
bioactive PAF. PAF then signals through its G-protein coupled receptor on various cells 
of the hematopoietic cell lineage. PAF receptor activation stimulates numerous complex 
signaling pathways that culminate in producing PAF’s diverse biological actions. Of 
note, PAF receptor activation results in the activation of cytosolic phospholipase A2 and 
the generation of lyso-PAF. A cycle of PAF producing PAF receptor activation and more 
PAF synthesis is established. In many of the cells that produce PAF, the fatty acid that is 
esterified at the sn-2 position of membrane phospholipids is arachidonic acid (7).
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Figure 3; Enzymatic Remodeling Pathway in PAF Synthesis. The enzymatic 
remodeling pathway is the primary means by which PAF is synthesized. The sn-2 
position o f choline containing membrane phospholipids is esterified by a cytoplasmic 
phospholipase A2 upon exposure to an inflammatory stimulus. The action o f the 
cytoplasmic phospholipase A2 generates lyso-PAF. After the formation o f lyso-PAF, 
PAF acetyltransferase transfers an acetate group to the sn-2 position generating bioactive 
PAF. From: McManus, L. M., and Pinckard, R. N. (2000) Critical Reviews in Oral 
Biology & Medicine 11, 240-258
As shown in Figure 4, arachidonic acid is the precursor for formation of the eicosanoids 
(8). Because of this, the formation of various eicosanoids such as thromboxanes and 
leukotrienes is often concomitant with the synthesis o f PAF. These lipids, working 
together, can augment the inflammatory response (1). In addition to the inflammatory 
response elicited by PAF, PAF-like phospholipids are also able to induce an 
inflammatory response. These PAF-like phospholipids are not derived enzymatically, but 
rather result from the oxidative fragmentation of membrane phospholipids. Unlike the
enzymatically derived PAF, whose synthesis is tightly regulated, the synthesis of these 
PAF-like phospholipids is not regulated (9) (10). Thus, a significant means to regulate 
the inflammatory response elicited by both PAF and PAF-like phospholipids is through 
the action of a family of enzymes known as PAF acetylhydrolases (PAF-AH).
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Figure 4: . Synthesis of Various Eicosanoids via Arachidonic Acid. Often, during the 
enzymatic synthesis of PAF, the fatty acid moiety that is esterified at the sn-2 position is 
arachidonic acid. This is of relevance because arachidonic acid is the precursor to various 
eicosanoids such as thromboxanes, prostaglandins and leukotrienes which can, in turn, 
augment the inflammatory response. From; Kantarci, A., and Van Dyke, T. E. (2003) Crit 
Rev Oral Biol Med 14, 4-12
The various PAF acetylhydrolases are calcium-independent phospholipase Ass 
which catalyze the removal o f the sn-1 acetate moiety, or variations at this position from 
PAF or PAF-like phospholipids. Such variations, as shown in Figure 2, may consist of 
oxidized functionalities derived from fragmentation of the long acyl chain of membrane 
phospholipids. The PAF acetylhydrolases convert the bioactive PAF to its biologically
inactive form lyso-PAF— thereby providing a means to interrupt the progression of an 
inflammatory response. There are two categories o f PAF acetylhydrolases: intracellular 
and secreted (11). The intracellular PAF acetylhydrolases are able to recognize a diverse 
array of PAF-like phospholipids and are found in various subcelluar locations. 
Additionally, the intracellular PAF acetylhydrolase has a wide range o f structures and can 
be either monomeric, dimeric or heterotrimeric (2). There are three subcategories of the 
intracellular PAF acetylhydrolases which include PAF acetylhydrolase Ib, PAF 
acetylhydrolase II and the erythrocyte PAF acetylhydrolase. The PAF acetylhydrolase Ib 
is thought to control PAF levels in the brain and mutations in the P-subunit of this 
enzyme cause Miller-Dieker lissencephaly (12). PAF acetylhydrolase II is a 40 kDa 
protein found in various tissues and has similar function to the plasma form of the 
enzyme— the main difference being a substrate preference for short acyl groups at the sn- 
2 position (13). The primary function of PAF acetylhydrolase II is the protection from 
damage induced by lipid oxidation (14). The erythrocyte PAF acetylhydrolase is 
composed of two identical 25 kDa subunits (15). The function of the erythrocyte PAF 
acetylhydrolase is intriguing because erythrocytes do not produce nor are they stimulated 
by PAF. Possibly, the erythrocyte PAF acetylhydrolase hydrolyzes oxidatively 
fragmented phospholipids which are usually formed in high oxygen situations or as 
byproducts of free radical reactions (16). Though the intracellular PAF acetylhydrolases 
are diverse and important in function, the primary focus of this research concerns the 
action of the plasma PAF acetylhydrolase.
The plasma form of PAF acetylhydrolase (referred to solely as PAF 
acetylhydrolase in subsequent use, unless otherwise noted) was isolated in 1985 by Farr
et al. and the cDNA was subsequently cloned in 1995 by Tjoelker et al. (17,18). The 
difficulty in purification of PAF acetylhydrolase was due to its association with LDL 
particles in the serum. Two-thirds of the PAF acetylhydrolase in serum is associated with 
LDL and the remaining one-third with HDL (19-21). The first seventeen residues of the 
protein encoded by the cDNA are hydrophobic and most likely direct the enzyme for 
secretion. The subsequent twenty-four residues are not found in the mature PAF 
acetylhydrolase and may represent a pre-pro-peptide. Additionally, the primary structure 
of PAF acetylhydrolase contains a GXSXG motif which is homologous to many lipases 
and serine esterases (22,23). The active sites of many serine esterases contain a serine, 
aspartate and histidine triad; a similar triad is found in the active site of PAF 
acetylhydrolase— indicating that the active site of both PAF acetylhydrolase and serine 
esterases may be similar.
Increases in PAF acetylhydrolase activity have been implicated in many disease 
states such as vascular disease, ischemic stroke and diabetes mellitus (24,25). Within the 
human population, the level o f activity of PAF acetylhydrolase varies five-fold— 60% of 
this variation is attributed to genetic factors where some of this variability can be 
attributed to varying levels of LDL-cholesterol (26,27). Because changes in activity of 
PAF acetylhydrolase may be linked to certain disease states, it is important to investigate 
whether PAF acetylhydrolase levels can be an indicator of disease— especially those with 
an inflammatory component. Numerous studies have shown strong correlations between 
PAF acetylhydrolase activity and LDL-cholesterol levels—with higher LDL-cholesterol 
levels accompanied by higher PAF acetylhydrolase levels. This is supported by patients 
with hypercholesterolemia treated with a HMG-CoA reductase inhibitor showing
decreased plasma PAF acetylhydrolase activity in conjunction with lower LDL- 
cholesterol levels (26,28). Individuals suffering from systemic lupus erythematosus also 
show decreased PAF acetylhydrolase levels alongside reduced LDL levels (29). Further, 
patients with lower pre-operative PAF acetylhydrolase enzyme levels were more prone to 
developing systemic inflammatory response syndrome after cardiac surgery as compared 
to patients with normal circulating PAF acetylhydrolase enzyme levels (30). Because the 
association of PAF acetylhydrolase activity and disease appears well correlated, it is 
important to investigate the ability of various proinflammatory mediators to regulate the 
expression of PAF acetylhydrolase and investigate the cellular pathways involved in such 
regulation. This research will aid in developing a clearer picture of the physiologic role 
played by this anti-inflammatory enzyme.
Lipopolysaccharide (LPS) is a component of the cell wall o f gram negative 
bacteria and all of the pathophysiological responses consequent to bacterial sepsis can be 
attributed to LPS. Further, purified LPS is utilized in the laboratory as a potent stimulator 
o f the inflammatory response to investigate specific cellular and biochemical processes. 
Recognition of LPS is accomplished through a complex interaction o f cell-surface 
receptors and co-receptors. (Figure 5). Briefly, LPS will interact with the LPS binding 
protein (LBP) and activate toll like receptor 4 (TLR-4) via CD 14— thus, initiating 
activation of the intracellular MAPK cascades (31). (See Figure 5). Work by Howard et 
al. demonstrated the in vivo upregulation of PAF acetylhydrolase mRNA levels in 
response to LPS challenge in rats. Specifically, the increased expression of PAF 
acetylhydrolase was detected in Kupffer cells, the resident macrophages of the liver (32). 
Further, previous literature has shown that in THP-1/CD14 cells, a human monocyte-like
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|D (L -)
w e AM JWP-t CRE MF-eB
Figure 5: LPS Signaling via MAPK Pathway. Upon exposure to lipopolysaccharide 
(LPS) in serum, LPS will interact with the lipopolysaccharide binding protein (LBP). 
This new LPS-LBP complex is delivered to a cell surface receptor called CD 14. CD 14 
then delivers LPS to a member of the toll-like receptor super family called toll like 
receptor 4 (TLR4). LPS binding to TLR4 activates the various portions o f the MAPK 
cascades and the transcription of various genes. Adapted from;
Guha, M., et al. Cellular Signaling 13 (2001) 85-94.
cell line that over expresses CD 14, the LPS-induced upregulation of PAF acetylhydrolase 
is solely p38MAPK dependent (33). In contrast, other researchers have documented that 
in cultured macrophages there is a decrease in PAF acetylhydrolase expression upon 
exposure to LPS (32,34). This observation may be related to the activation of these 
macrophages in vitro and adherence to the cell culture vessel. Because TNF-a and PAF 
are known pro-inflammatory mediators and activators of macrophages, an investigation
10
of their ability to upregulate PAF acetylhydrolase mRNA levels was deemed pertinent. 
PAF, as discussed above, is a potent pro-inflammatory phospholipid whose signaling is 
mediated by the seven membrane spanning G-protein coupled receptor. Additionally, 
TNF-a, a cytokine, primarily produced by macrophages, is involved in acute systemic 
inflammation (35).
In order to investigate the mechanism of increased PAF acetylhydrolase 
expression in response to inflammatory mediators, monocyte-macrophage 6 cells (MM6) 
were used because initial experiments demonstrated the MM6 cells increased PAF 
acetylhydrolase expression in response to LPS exposure (36)— a result identical to that 
detected in macrophages in vivo. This physiologically relevant cell line spans the 
monocyte macrophage differentiation lineage, is derived from a human leukemia patient, 
and grows in suspension. The latter fact is important because adherent macrophage cell 
lines, such as the RAW264.7 cell line, demonstrate opposite effects of LPS-induced PAF 
acetylhydrolase induction with respect to the response observed in vivo (i.e. LPS 
decreases PAF acetylhydrolase expression in vivo). Monocytes/macrophages are part of 
the non-specific innate immune system in which the inflammatory response is involved. 
In contrast, the slower, yet more specific, adaptive immune system is antigen dependent 
and does not directly involve macrophages/monocytes. However, macrophages are 
antigen-presenting cells. After an invading microbe is phagocytosed by a macrophage, 
the macrophage presents the peptide fragments of the microbe on it surface via class II 
MHC. Via CD4 co-receptor interaction, macrophages are able to activate helper T-cells 
which, via secretion of various interleukins, activate the antibody producing B-cells. 
Thus, macrophages able to provide a link to the innate immune response via helper T-cell
11
activation. Thus, because MM6 cells represent a physiologically relevant cell culture 
model, they were used in all subsequent experiments in this study.
To investigate the ability of PAF and TNF-a to alter PAF acetylhydrolase 
expression and to ascertain any similarities or differences to the LPS-induced signaling 
pathways Real-Time PCRs, ELISAs, and an inducer of reactive oxygen species, tert- 
butyl hydroperoxide, were all employed. In this study, we were able to demonstrate the 
ability of both TNF-a and PAF to upregulate PAF acetylhydrolase expression. In 
addition, we examined the various signaling pathways involved in the upregulation of 
PAF acetylhydrolase mRNA and were able to gain a greater understanding o f the various 
MAPK cascades involved in PAF acetylhydrolase mRNA upregulation. Further, we 
demonstrated that reactive oxygen species may play a role in inducing PAF 
acetylhydrolase expression and that the LPS-induced upregulation of PAF 
acetylhydrolase mRNA levels also involves the PAF receptor.
12
CHAPTER 2
MATERIALS AND METHODS
2.1 Materials
Monocyte-Macrophage 6 cells (A generous gift from Shamim Mustafa), Fetal Bovine 
Serum (Atlanta Biological), Penicillin/Streptomycin (HyClone), Non-essential amino 
acids (HyClone), RPMI Media (Cellgro), Lipopolysaccharide (Sigma), Platelet 
Activating Factor (Sigma), TNF-a ( Sigma), High capacity cDNA Reaction Kit (Applied 
Biosystems), 2x Universal PCR Master Mix (Applied Biosystems), TaqMan Primers 
(Applied Biosystems), Live Green ROS Detection Kit (Invitrogen), All ELISA kits 
(R&D Systems).
2.2 Maintenance o f  the Human Monocyte-Macrophage 6 Cell Line 
Human Monocyte-Macrophage 6 (MM6) cells, derived from a Leukemia patient and 
grown in suspension, were obtained from Dr. Shamim Mustafa and were stored at 
-180°C. Upon use, ImL of MM6 cells were quickly thawed from deep freeze and were 
resuspended in 10 mU RPMI media supplemented with the following components in their 
final concentrations: 10% fetal bovine serum, 10000 U/mL Penicillin, 10000 pg/mL 
Streptomycin, 1 mM oxaloacetate, 0.45 mM pyruvate, 0.2 U/ml insulin, and Ix non- 
essential amino acids. The MM6 cells were counted with the use o f a hemocytometer, 
centrifuged and were seeded in a twenty-four well tissue culture plate at an initial density
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of 5x10^ cells/mL with 2 mL/well o f complete media and cultured overnight. 
Subsequently, MM6 cells were seeded at a density of 2x10^ cell/well in twenty-four well 
tissues culture plates (2 mL/well) for each subsequent passage. Cells were maintained at 
37°C, in a humidified 5% CO2 atmosphere for 2-3 days before use in any subsequent 
experiments. MM6 cells were split every two days, and the cells used in all experiments 
did not exceed sixteen passages.
2.3 Isolation and Quantization o f  RNA 
All RNA isolation procedures were based on the method outlined by Sacchi and 
Chomczynski (37). MM6 cells were pelleted by centrifugation and were lysed in 1 mL 
TRIzol Reagent by repetitive pipetting. Lysates were transferred to 1.5 mL eppendorf 
tubes. For each 1 mL of TRIzol Reagent, 200 pL chloroform was added to each sample 
tube. Sample tubes were shaken vigorously for fifteen seconds and incubated at 15 to 
30°C for 2-3 minutes. Samples were then centrifuged at 12,000xg for 15 minutes at 4°C. 
The clear upper aqueous phase was transferred to a new eppendorf tube and 500 pL 
isopropyl alcohol was added per ImL of TRIzol Reagent initially used. The sample tube 
was shaken vigorously for fifteen seconds and centrifuged at 12,000xg for thirty-minutes 
at 4°C to pellet the RNA. The supernatant was removed and RNA pellets were washed 
with 1 mL cold 75% ethanol per mL of TRIzol Reagent initially used. Sample tubes were 
then mixed vigorously by vortexing and were centrifuged at 7,500xg for 5 min at 4°C. 
The supernatant was removed and the RNA pellet was allowed to air dry for five- 
minutes. RNA pellets were then resuspended in 40 pL diethyl pyrocarbonate treated
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water. To quantify the isolated RNA, 3 pL of sample was diluted in 197 pL of Mili-Q 
water in a 96-well low-UV plate. The Spectra Max Plus microplate reader was used to 
obtain the optical density at 260nm and 280nm. The absorbance units at 260 nm provided 
the RNA concentration and the 260/280 ratio indicated the purity of the RNA.
2.4 Performance o f  cDNA Synthesis
Five pg RNA was reverse transcribed in 60 pL cDNA reactions with use of the High 
Capacity cDNA synthesis kit supplied by Applied Biosystems. Random Primers were 
used to initiate the cDNA synthesis and were supplied at lOx, Multiscribe for reverse 
transcription was supplied at 50 U/pL, the Reverse Transcriptase buffer was supplied as a 
lOx solution and 25x dNTP buffer was supplied at a 100 mM concentration. All samples 
were mixed in their appropriate concentrations to give a Ix solution. Multiscribe was 
diluted to a final concentration o f 75 U/pL and the 25 dNTP buffer was prepared at a 
final concentration 4 mM. Prepared samples were heated to 25°C for ten minutes and 
then 37°C for two hours using the GeneAmp PCR systems 2400 machine.
2.5 Performance o f  Real-Time PCR
Thirty pL Real-Time PCR reactions were performed using 5 pL o f cDNA created as 
described above. TaqMan primers (20x) specific for the human PAF acetylhydrolase and 
18S ribosomal RNA and Universal PCR Master Mix (2x) were obtained from Applied 
Biosystems. Real-time PCRs were performed on the Applied Biosystems 7000 Real-
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Time PCR machine to amplify the PAF acetylhydrolase cDNA. To make this method 
quantitative, four, five-fold serial dilutions o f cDNA was reverse transcribed from 6 pg of 
RNA isolated from LPS treated MM6 cells and were run simultaneously with the 
experimentally derived cDNAs. Each dilution was assigned an arbitrary numerical value 
that was indicative of a five-fold serial dilution. In this way a quantitative numerical 
value is obtained where fold-induction in PAF acetylhydrolase levels over control can be 
ascertained. To correct for slight differences in RNA concentration, 18S levels were 
analyzed by Real-Time PCR as described above and the ratio of PAF-AH to 18S levels 
was determined. See Figure 6.
2.6 Performance o f  Dose Response Experiments 
MM6 cells were seeded at a density of 2x10^ cells/mL in 2 mL of complete media, and 
were incubated in a humidified 5% CO2 environment at 37°C for twenty-four hours prior 
to the start o f any experiments. Subsequent to this, dose response experiments were 
performed for PAF, in its most potent form (l-0-Hexadecyl-2-0-acetyl-sn-glycero-3- 
phosphocholine), LPS (from E. coli, serotype: 011LB4) and TNF-a. The PAF was 
prepared as a 100 mM stock solution dissolved in chloroform. Ten pL of the stock 
solution was dissolved in 990 pL anhydrous ethanol. The 1 mL solution was dried under 
a N 2 gas stream. The dried PAF was then resuspended in 240 pL phosphate buffered 
saline (PBS) supplemented with 1% Bovine Serum Albumin (BSA) and sonicated for 
ten-minutes before use in any experiments. A 2 mg/mL stock solution of LPS was 
dissolved in IxPBS. Before use in experiments, 10 pL of the 2 mg/mL stock was 
dissolved in 90 pL IxPBS.
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Figure 6: Real-Time PCR PAF-AH and 18S Standard Curves. A. FAF
acetylhydrolase standards were prepared by reverse transcribing 6 pg of RNA to cDNA. 
Using the cDNA, four, five-fold serial dilutions were used to generate each standard. The 
undiluted standard was given an arbitrary value of 500 units. Each subsequent dilution 
was given a value indicative of a five fold serial dilution. B. 18s standards were generated 
by reverse transcribing 6 pg of RNA to cDNA. An initial 1:100 dilution was made of the 
cDNA. From this, a series of four, five-fold serial dilutions were generated and assigned 
values in the same manner as described in part A. above.
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A 25 mM stock solution of TNF-a was prepared dissolved in IxPBS. PAF was 
administered to MM6 cells at concentration of 0 pM, 0.125 pM, 0.25 pM and 0.5 pM. 
LPS was administered at concentration of 0 ng/mL, 50 ng/mL, 100 ng/mL and 200 
ng/mL. TNF-a was administered at concentrations of 0 ng/mL, 5 ng/mL, 10 ng/mL and 
20 ng/mL. At twenty-four hours after administration, the cells were harvested by 
centrifugation and RNA was isolated, reverse transcribed to cDNA and Real-Time PCR 
experiments were performed.
2.7 Performance o f  Seventy-two Hour Time Course Experiments 
MM6 cells were seeded at a density of 2xl0^cells/mL in 2 mL of complete media, 
cultured for twenty-four hours and were then treated with either 200 ng/mL LPS, 10 
ng/mL TNF-a or 0.5 pM PAF. In each experimental condition cells were incubated with 
either o f the aforementioned pro-inflammatory mediators for 0, 1,3, 6, 12, 24, 48, and 72 
hours. For LPS treated cells, seventy-two hour time course experiments were also run in 
the absence of 10% FBS by washing copiously with IxPBS and resuspending in RPMl 
lacking serum. MM6 cells were also incubated for seventy-two hours in the absence of 
LPS for both serum containing and serum free RPML After each time point, RNA was 
isolated, reverse transcribed to cDNA and analyzed in real-time PCR experiments as 
described above.
2.8 Performance o f  Synergistic PAF-AH Induction 
MM6 cells were seeded at a density of 2x10^ cells/mL in 2 mL of complete media, 
cultured for twenty-four hours and were then treated with either 200 ng/mL LPS, 10
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ng/mL TNF-a or 0.5 pM PAF. In addition, various combinations of the aforementioned 
mediators were dually administered in each well. MM6 cells were cultured for twenty- 
four hours and RNA was isolated, reverse transcribed to cDNA and analyzed in Real- 
Time PCR experiments.
2.9 Performance o f  MAPK inhibition experiments 
MM6 cells were seeded at a density of 2xl0^cells/mL in 2mL of complete media, 
cultured for twenty-four hours and were then treated with either 15pM SB203580 
(p38MAPK inhibitor) or 15pM PD980058 (ERR 1/2 inhibitor) one hour prior to addition 
of either 200 ng/mL LPS, 0.5 pM PAF, or 10 ng/mL TNF-a. Cells were then harvested 
twenty-four hours later and RNA was isolated, reverse transcribed to cDNA and analyzed 
by real-time PCR experiments as described above.
2 .\0  Preparation o f  MM6 cells fo r  ELIS As 
MM6 cells were plated in serum-containing RPMl media for twenty-four hours as 
described above. MM6 cells were then switched into serum free media, after multiple 
wash steps with Ix PBS, and seeded at density of 4x10^ cells/mL and allowed to incubate 
overnight. Five-hundred ng/mL LPS were administered and MM6 cells were incubated 
for twenty-four hours. Cells were harvested at various time points and centrifuged. 
Conditioned media were collected and stored at -20°C. Cell pellets were lysed with lysis 
buffer containing phosphatase inhibitors and preservatives supplied by R&D Systems. 
Cells lysates were then supplemented with protease inhibitor cocktail from Sigma before 
use in subsequent experiments.
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2.11 Performance o f  ELISA fo r  IL-1^
ELISA kits were obtained from R&D Systems. The Quantikine Human IL -ip /1L-1F2 kit 
was used to assay for IL-ip. All supplied reagents were prepared according to the 
manufacturers instructions. Two-hundred pL of standard, sample or control were applied 
to antibody coated wells supplied by the manufacturer and allowed to incubate for two 
hours at room temperature. Wells were then aspirated and washed three times with wash 
buffer containing surfactant and preservatives four times. Two-hundred pL of a 
polyclonal antibody against IL -ip conjugated to horseradish peroxidase was then loaded 
into each well and incubated for one hour. Again, wells were aspirated and washed three 
times. A two-hundred pL mixture of stabilized horseradish peroxidase and chromogen 
(trimethylbenzidine) were then added to each well and incubated, protected from light, 
for twenty-minutes. Fifty pL of a 2N sulfuric acid stop solution was added to each well 
and the absorbance determined at 450 nm with wavelength correction at 540 nm within 
thirty-minutes of addition of the stop solution. A standard curve was generated using a 
four parameter logistic curve fit.
2.12 Performance o f  ELISA fo r  TNF-a
ELISA kits were obtained from R&D Systems. The Quantikine Human TNF-a /SFIA kit 
was used to assay for TNF-a. All supplied reagents were prepared according to the 
manufacturers instructions. Fifty pL of the provided Assay Diluent RDIF was added to 
each antibody coated well. 200 pL of standard, control or sample were added to each well 
and allowed to incubate for two hours. Wells were then aspirated and washed with wash 
buffer containing surfactant and preservatives four times. Two-hundred pL of a
20
polyclonal antibody against TNF- a conjugate to horseradish peroxidase was added to 
each well and incubated for one hour. Wells were then aspirated and washed four times. 
A 200 pL mixture of stabilized hydrogen peroxide and chromogen (trimethylbenzidine) 
was then added to each well and incubated, protected from light, for twenty-minutes. 
Fifty pL o f 2N sulfuric acid stop solution was added to each well and absorbance 
determined at 450 nm with wavelength correction at 540 nm within thirty-minutes. A 
standard curve was created using a four parameter logistic curve fit.
2.13 Performance o f  ELISA fo r  Phospho-p38a 
ELISA kits were obtained from R&D Systems. The Surveyor 1C kit was used to assay for 
Phospho-p38a. All supplied reagents were prepared according to the manufacturers 
instructions. One-hundred pL of standard, sample or control were added to each antibody 
coated well and incubated for two hours. Wells were then aspirated and washed with 
wash buffer containing surfactant and preservatives four times. One-hundred pL of 
strepavidin-horseradish peroxidase was added to each well and incubated for twenty- 
minutes. A 100 pL mixture of stabilized hydrogen peroxide and chromogen 
(trimethylbenzidine) was then added to each well and incubated, protected from light, for 
twenty-minutes. Fifty pL of stop solution was added to each well and absorbance 
determined at 450nm with wavelength correction at 540nm within thirty-minutes. A 
standard curve was fit using a four parameter logistic curve fit.
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2.14 Performance o f  PAF Receptor Antagonist Experiments 
MM6 cells were cultured in serum-containing media at a density of 2x10^ cells/mL and 
used in experiments twenty-four hours later. The PAF receptor antagonist, WEB2170 
was a generous gift provided by Merle S. Olson, University of Texas Health Sciences 
center. The p38MAPK inhibitor, SB203580, and the PAF receptor antagonist, WEB2170, 
were administered either one-hour or fifteen-minutes prior to administration of LPS or 
PAF respectively. In instances where WEB2I70 and SB203580 were administered 
dually, WEB2I70 and SB203580 were administered immediately together followed by 
LPS and PAF administration one hour later. Cells were harvested at twenty-four hours 
and RNA was isolated based on the method outlined by Sacchi and Chomczynski. Five 
pg of RNA, for each experimental condition, were reverse transcribed to cDNA and were 
used in Real-Time PCR reactions as described above.
2.15 Performance o f  Reactive Oxygen Species Induction 
MM6 cells were cultured in serum-containing media at the appropriate density as 
described above. Two pL of a 100 mM tert- butyl hydroperoxide (TBHP) stock solution 
was administered to MM6 cells in the 2 mL cell culture plates, in complete media, to 
produce a final concentration of 100 pM TBHP on the cells. Cells were harvested at 0, 1, 
3, 6, 12 and 24 hours and RNA was isolated as described above. Five pg of RNA, for 
each experimental condition, were reverse transcribed to cDNA and were used in Real- 
Time PCR reactions.
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2.16 Identifying Morphological Changes in MM6 Cells 
Various combinations of 0.5 pM PAF, 200 ng/mL LPS and 10 ng/mL TNF- a  were 
administered to MM6 cells in serum-containing media. Twenty-four hours later, pictures 
o f the MM6 cells were taken through use a digital camera attached to a Zeiss Axiovert 
inverted microscope (Gottingen, Germany). Pictures were taken at a total magnification 
of50X.
2.17 Performance o f  Statistical Analysis 
T-tests were conducted to determine if  there were significant differences 
between selected variables (i.e. varying doses of LPS treatment vs. control) where 
comparisons were made between one control group and one treatment group. Analysis of 
variance (ANCVA) were conducted to determine if there were significant differences 
between selected variables (i.e. PAF-AH mRNA fold-induction over control in the 
presence of various inhibitors and inflammatory mediators ) where comparisons were 
made between a control group and more than one treatment group. Repeated measures 
were conducted between selected variables (i.e. seventy-two hour time course 
experiments in the presence of various inflammatory mediators) where comparisons were 
made between one control group and one treatment group across several time periods. All 
analyses were conducted using SPSS 16.0 (SPSS, Inc., Chicago, IL).
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CHAPTER 3 
RESULTS
The goal of this research is to investigate whether TNF-a and PAF are able to upregulate 
PAF acetylhydrolase expression and, to ascertain any similarities or differences in 
signaling to that detected with LPS. Cultured MM6 cells were used in experiments for 
their ability to induce PAF acetylhydrolase expression in response to LPS in vitro— 
similar to the response demonstrated in vivo.
3.1 Dose Response o f  Various Pro-inflammatory Mediators 
In order to determine if  LPS, PAF and TNF-a are able to upregulate PAF acetylhydrolase 
expression, dose response experiments, measuring the fold induction of PAF 
acetylhydrolase mRNA, were performed. See Figures 7-9. MM6 cells were cultured in 
serum-containing media for twenty-four hours prior to administration o f the 
proinflammatory mediators. After a twenty-four hour inflammatory challenge with the 
aforementioned mediators, PAF acetylhydrolase mRNA levels were ascertained through 
Real-Time PCR. For all doses of LPS, a 15-20 fold induction of PAF acetylhydrolase 
mRNA was observed over control levels as shown in Figure 7. One-hundred ng/mL LPS 
produced a maximal 20-fold induction in PAF acetylhydrolase levels over control. At 200 
ng/mL LPS, PAF acetylhydrolase mRNA levels decreased slightly from the maximal 
values but still resulted in a sixteen-fold induction over control levels. For all of the
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concentrations of PAF, a 3.5-4.5 fold induction of PAF acetylhydrolase message was 
observed. (See Figure 8). However, the upregulation of PAF acetylhydrolase levels did 
not appear to be dose-dependent—though, some variability was detected. The TNF-a 
induced PAF acetylhydrolase levels showed a 6.5-10 fold induction o f PAF 
acetylhydrolase message over control for all concentrations of TNF-a administered. As 
shown in Figure 9, incremental increases in PAF acetylhydrolase mRNA were observed 
for increasing concentrations of TNF-a. Administration of 20 ng/mL TNF-a resulted in 
the largest increase in PAF acetylhydrolase (10-fold) however, higher concentrations 
were not tested.
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Figure 7: LPS Dose Response. MM6 cells were cultured in serum-containing media for 
twenty-four hours. Incremental increases in PAF-AH mRNA levels are observed up 100 
ng/mL LPS administration. At 200 ng/mL LPS administration, MM6 cells appear to 
become desensitized to the increase LPS administration. The data reflect a value of two 
independent biological samples analyzed in triplicate; mean difference is significant at 
p<0.05. The single asterisk represents statistical significance from all other values. Error 
bars represented are +/- standard deviation.
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Figure 8: PAF Dose Response. MM6 cells were cultured in serum-containing media for 
twenty-four hours in the presence of various concentrations of PAF. The PAF induced 
PAF-AH mRNA levels do not appear to be dose dependent. This is observation is most 
likely due to the presence of PAF-AH in the 10% FBS. Fold-induction of PAF-AH levels 
is statistically different than control for all concentrations of PAF administered. The data 
reflect a value of two independent biological samples analyzed in triplicate; mean 
difference is significant at p<0.05. Single asterisk represents statistical difference 
between 0.25pM PAF and 0.5pM PAF. Error bars represented are +/- standard deviation.
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Figure 9: TNF-a Dose Response. MM6 cells were cultured in serum-containing media 
for twenty-four hours. The TNF-a induced upregulation of PAF acetylhydrolase shows 
increased expression of PAF acetylhydrolase with incremental increase in TNF-a dosage. 
The data reflect a value of two independent biological samples analyzed in triplicate; 
mean difference is significant at p<0.05. The single asterisk represents statistical 
significance from the control. Error bars represented are +/- standard deviation.
3.2 Lipopolysaccharide Induced Expression o f  PAF-AH mRNA in MM6 Cells 
LPS is a component of the cell wall of gram-negative bacteria and is known to elicit pro- 
inflammatory responses that result in the upregulation of PAF Acetylhydrolase levels in 
vivo. In order to characterize the extent and time frame of the LPS induced PAF 
acetylhydrolase response, MM6 cells were cultured with 200 ng/mL LPS over a seventy- 
two hour period in either serum-containing or serum-free RPMl media. See Figures 10 
and 11. Time course experiments for MM6 cells cultured in serum-containing media 
showed control levels o f PAF Acetylhydrolase mRNA levels after one hour of LPS 
treatment. Subsequent to this, PAF Acetylhydrolase mRNA levels rose steadily— 
reaching a maximal 8-fold induction, compared to control levels, at twenty-four hours. At
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forty-eight and seventy-two hours, PAF acetylhydrolase mRNA levels slightly decreased 
to a level that was approximately six-fold above control levels. Control cells, not 
receiving any LPS treatment, were incubated for the entire time course. Near control 
levels of PAF acetylhydrolase were detected in all samples.
In order to determine the importance of the lipopolysaccharide binding protein 
(LBP) in mediating the effects of LPS with respect to PAF Acetylhydrolase mRNA 
upregulation, MM6 cells were cultured in serum-free media with either 200 ng/mL LPS 
or in the absence of LPS for seventy-two hours as shown in Figure 11. In the absence of 
serum, PAF acetylhydrolase mRNA levels were similar to levels detected after exposure 
to 200 ng/mL LPS in serum-containing media for the initial twenty-four hours. 
Subsequent to this time, an approximately thirty and sixty fold increase in PAF 
acetylhydrolase mRNA levels was detected at forty-eighty and seventy two hours 
respectively in both MM6 cells cultured in serum-free media in the presence or absence 
of LPS.
3.3 Platelet Activating Factor Induced Expression o f  PAF- A H  mRNA in MM6 Cells
PAF is a known potent phospholipid aetivator and mediator of many leukoeyte 
funetions, ineluding platelet aggregation, inflammation, anaphylaxis and has been shown 
to be a eentral mediator in indueing an inflammatory response (38). The enzyme PAF 
aeetylhydrolase, a ealeium-independent phospholipase A 2 , eonverts PAF to its 
biologieally inaetive form, lyso-PAF. This relationship between PAF and PAF 
aeetylhydrolase suggests that the presenee o f PAF may upregulate PAF aeetylhydrolase 
expression. To investigate the extent, if  any, by whieh PAF is able to upregulate PAF
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acetylhydrolase mRNA levels, MM6 cells were cultured for seventy-two hours in serum- 
containing RPMl media in the presence of 0.5 pM PAF. (See Figure 12). Near control
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Figure 10: Serum-Containing Seventy-two Hour Time Course. MM6 cells were 
cultured for seventy-two hours in serum-containing RPMl media in the presence of either 
200 ng/mL LPS or 0 ng/mL LPS. For MM6 cells incubated in the presence of serum, 
maximal fold induction of PAF acetylhydrolase levels occur at twenty-four hours. Levels 
drop by forty-eight hours and a slight increase in PAF acetylhydrolase induction is 
observed at seventy-two hours. MM6 cells cultured in absence of LPS show near control 
levels of PAF acetylhydrolase induction. The data reflect a value of two independent 
biological samples analyzed in triplicate; mean difference is significant at p<0.05. The 
single asterisks represent statistical significance from control. Error bars represented are 
+/- standard deviation.
levels of PAF acetylhydrolase mRNA expression were observed within six hours of 0.5 
pM PAF exposure. PAF Acetylhydrolase mRNA levels increase five-fold over control 
levels at twelve hours of 0.5 pM PAF exposure. PAF acetylhydrolase levels fall to eight­
fold over control by seventy-two hours.
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Figure 11; Serum-Free Seventy-two Hour Time Course. MM6 cells incubated in 
serum free RPMl with either 200 ng/mL LPS or 0 ng/mL LPS over a seventy-two hour 
time course. Fold induction of PAF acetylhydrolase between the two experimental 
conditions show no statistical difference. The data reflect a value of four independent 
biological samples analyzed in triplicate for LPS-induced cells; The data reflect a value 
o f two independent biological samples analyzed in triplicate for control cells. There was 
no statistical difference between control and experimental conditions. Error bars 
represented are +/- standard deviation.
3.4 Tumor Necrosis Factor- a Induced Expression o f  PAF-AH mRNA in MM6 Cells 
TNF-a is a 17 kDa cytokine involved in acute phase systemic inflammation. TNF-a is 
mainly produced by macrophages, but also by a broad variety o f other cell types 
including lymphoid cells, mast cells, and endothelial cells. Large amounts o f TNF-a are 
released in response to lipopolysaccharide, other bacterial products, and interleukin-1 
(39) (35). To investigate the extent and time frame by which TNF-a is able to upregulate 
PAF acetylhydrolase mRNA levels in MM6 cells, cells were cultured for seventy-two 
hours in the presence of 10 ng/mL TNF-a in serum-containing media.
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Figure 12: PAF Induced Serum-Containing Seventy-two Hour Time Course. MM6
were cultured in serum containing RPMl media for seventy-two hours in the presence of 
0.5 pM PAF. Levels of PAF acetylhydrolase induction remain relatively steady upon until 
12 hours of PAF exposure. The data reflect a value of two independent biological 
samples analyzed in triplicate; mean difference is significant at p<0.05. Single asterisk 
represents statistical difference from the control. Error bars represented are +/- standard 
deviation.
As shown in Figure 13, levels of PAF acetylhydrolase mRNA remained steady, near 
control levels, up until six hours of exposure to TNF-a— where a two-fold induction, 
above control levels, was observed. PAF acetylhydrolase levels increased nine-fold, 
above control levels, at twenty-four hours o f TNF-a exposure and abruptly returned to 
control levels by seventy-two hours.
31
TNF-a Induced Increase in PAF-AH
(O
00
LL
10 
9 4 
8 
7 
6 
5 
4 
3 
2 
1 
0 . i i .
12 24 4 8  72
Hours
Figure 13: TNF-a Serum-Containing Seventy-two Hour Time Course. MM6 cells 
were cultured in serum-containing RPMl media for seventy-two hours in the presence of 
10 ng/mL TNF-a. Levels of PAF acetylhydrolase induction begin to rise by three hours 
and reach maximal levels of induction by twenty-four hours. PAF acetylhydrolase levels 
then drop abruptly by seventy-two hours. The data reflect a value of two independent 
biological samples analyzed in triplicate; mean difference is significant at p<0.05. Single 
asterisk represents statistical difference from the control. Error bars represented are 4-/- 
standard deviation.
3.5 PAF-AH mRNA Induction in Response to Dually Administered Pro-Inflammatory
Mediators
Recent work by Stafforini et al. has shown that LPS-induced PAF Acetylhydrolase 
upregulation is mediated entirely through p38MAPK in the monocyte-like cell line, THP- 
1/CD14 (40). In order to determine if PAF, TNF-a, and LPS can augment function in a 
synergistic manner, combinations of dually administered pro-inflammatory mediators 
were added to a MM6 cell culture and the levels of PAF acetylhydrolase mRNA were 
determined. Administration of either 200 ng/mL LPS, 10 ng/mL TNF-a, or 0.5pM PAF 
showed a 15, 12 and 4.5-fold induction over control PAF acetylhydrolase mRNA levels,
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respectively. The effects o f the dually administered pro-inflammatory mediators are 
shown in Figure 14.
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Figure 14: Dual Administration of Proinflammatory Mediators. MM6 cells were 
cultured in serum containing RPMl media and were incubated with various combinations 
of proinflammatory mediators. Strong fold induction of PAF acetylhydrolase mRNA 
levels were observed with LPS and TNF-a administered in combination and near additive 
effects in PAF acetylhydrolase induction were observed for TNF-a + PAF and LPS + 
PAF. The data reflect a value of two independent biological samples analyzed in 
triplicate; mean difference is significant at p<0.05. The single asterisk represents 
statistical difference from LPS-induced cells. The double asterisk represents statistical 
difference from TNF-a induced cells. The triple asterisk represents statistical difference 
from PAF-induced cells. Error bars represented are +/- standard deviation.
The combination of LPS and TNF-a showed a marked increase of forty-five fold 
induction over control levels at twenty-four hours. TNF-a + PAF and LPS + PAF showed 
a more modest synergistic twenty-five and twenty-two fold increase in PAF 
acetylhydrolase levels over control respectively. These latter results showed a near 
additive effect in PAF acetylhydrolase mRNA upregulation.
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3.6 Determination o f  Essential MAPK Signaling Pathways fo r  LPS, PAF and TNF-a 
LPS is able to induce proinflammatory responses via activation of numerous intracellular 
signaling pathways. A recent review article summarized the major pathways activated by 
LPS. These pathways include the MAPK cascades—ERKl/2, JNK, and p38— as well as 
the NFkp/Ikp intracellular signaling pathway (31). (See Figure 5). In order to investigate 
if  the MAPK pathways are essential for upregulation of PAF acetylhydrolase, and 
whether PAF and TNF-a also signal through similar mechanisms, use of various MAPK 
inhibitors were employed. The inhibitors, PD98059 and SB203580 were used to inhibit 
the ERKl/2 and p38MAPK portions of the MAPK pathway respectively as shown in 
Figures 15-17. MM6 cells were cultured in serum-containing media and were 
administered the inhibitors one-hour prior to administration of the proinflammatory 
agonist. Use of 15 pM SB203580 showed an approximately 50% decrease in PAF 
acetylhydrolase levels compared to MM6 cells treated with 200 ng/mL LPS alone as 
depicted Figure 15. A more modest 20% decrease in TNF-a mediated PAF 
Acetylhydrolase levels was observed with the inhibitor as compared to cells treated with 
10 ng/mL TNF-a alone. (Figure 15). Administration of SB203580 also decreased the 
PAF-induced PAF acetylhydrolase levels by approximately 20%. (Figure 17). 
Paradoxically, inhibition o f the ERKl/2 portion of the MAPK pathway with 15 pM 
PD98059 increased PAF acetylhydrolase expression by 50% relative to administration of 
the pro-inflammatory mediators alone for LPS, PAF and TNF-a. (Figures 16 and 17).
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Figure 15: Inhibition of p38MAPK signaling via SB203580. MM6 cells treated with 
either 200 ng/mL LPS or 10 ng/mL TNF-a were cultured in serum-containing RPMl 
media for twenty four hours in the presence o f the pBSMAPK inhibitor, SB203580 at 
15pM. A 50% decrease in LPS induced PAF-AH mRNA levels is observed in the 
presence o f SB203580. An approximately 20% decrease in the PAF induced PAF-AH 
mRNA levels is observed in the presence o f SB203580. Fold-induction o f PAF-AH 
mRNA levels is statistically significant from control and SB203580 for all other 
experimental conditions. The data reflect a value of two independent biological samples 
analyzed in triplicate; mean difference is significant at p<0.05. The single asterisk 
represents a statistical difference between LPS and LPS + SB203580 treated cells. Error 
bars represented are +/- standard deviation.
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Figure 16: Inhibition of ERKl/2 Signaling via PD98059. MM6 cells, cultured in 
serum-containing media for twenty-four hours show a 50% increase in PAF-AH mRNA 
levels (with respect to the inflammatory mediator administered) upon administration of 
the ERKl/2 inhibitor PD98058 at 15 pM. LPS was administered at a concentration 200 
ng/mL and TNF-a was administered at a concentration of 10 ng/mL. This result is most 
likely due to the stress imposed on the cell after inhibition of such a crucial pathway. See 
text. All experimental conditions are statistically different than control and PD98059 
administration. The data reflect a value of two independent biological samples analyzed 
in triplicate; mean difference is significant at p<0.05. The single asterisk represents 
statistical difference between LPS and LPS + PD98059 treated cells. The double asterisk 
represents statistical difference between TNF-a and TNF-a + PD98059 treated cells. 
Error bars represented are +/- standard deviation.
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Figure 17: Inhibition of p38MAPK and ERKl/2 Signaling via SB203580 and 
PD98059 Respectively. A.MM6 cells cultured in serum containing RPMl media were 
exposed to 15 pM SB203580 and 15 pM PD98059. The PAF induced PAF 
acetylhydrolase mRNA upregulation was decreased by approximately 20% in the 
presence of the p38 MAPK inhibitor. Paradoxically, inhibition of the ERKl/2 portion of 
the MAPK pathway caused an approximately 50% increase in fold induction o f PAF 
acetylhydrolase levels over the induction elicited by PAF alone. PAF was administered at 
a concentration of 0.5 pM. The data reflect a value of two independent biological 
samples analyzed in triplicate; mean difference is significant at p<0.05. The single 
asterisk represents a statistical difference between PAF and PAF + PD98059 treated cells. 
Error bars represented are +/- standard deviation.
3.7 PAF- AH  mRNA induction in Response to Dual Administration o f  SB203580 and
WEB2170
Recent work by Howard et al. suggested that 50% of the LPS-induced PAF 
acetylhydrolase response in rats is due to increased signaling through the PAF receptor as 
a result of increased PAF production due to LPS challenge (32). Further, our work 
showed only a 50% inhibition of the LPS-induced PAF acetylhydrolase mRNA 
upregulation upon administration of SB203580. In order to investigate if increased PAF 
signaling through its receptor contributes to the upregulation of PAF acetylhydrolase.
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MM6 cells were either singly or dually administered WEB2170 (50 pM) and SB203580 
(15 pM) prior to stimulation with PAF or LPS in serum-containing media for twenty-four 
hours. Figure 18 showed WEB2170 as an effective PAF receptor antagonist and inhibited 
the PAF-induced increase in PAF acetylhydrolase. Both LPS and PAF, alone, showed the 
typical fold induction of PAF acetylhydrolase levels over control. As seen previously, a 
50% decrease in the LPS-induced PAF acetylhydrolase mRNA, upon administration of 
SB203580, was observed. Administration of WEB2170, inhibited the LPS-induced 
increase in PAF acetylhydrolase resulting in a two-fold induction over control levels. 
Dual administration of both SB203580 and WEB2170, completely abolished the LPS- 
induced PAF acetylhydrolase levels and depressed PAF acetylhydrolase mRNA to half of 
that detected in control cells.
3.8 ZL-7P Induction in Response to LPS Treatment 
IL-ip, primarily produced by both monocytes and macrophages, is a known cytokine that 
aids in the induction of an inflammatory response (41). Because IL -ip production is 
increased in response to bacterial endotoxin, it was necessary to ascertain if the 
administration of LPS was able to induce IL -ip production in our MM6 cell culture 
model. In preparation for use in ELISAs, MM6 cells were grown in serum-containing 
media for twenty-four hours and then switched to serum-free media. After seven-hours in 
serum-free media, a 500 ng/mL dose of LPS was administered. MM6 cells were 
centrifuged; supemates were harvested and then used in subsequent ELISAs. As shown 
in Figure 19A, IL -ip protein levels increased to 115 pg/mL by three-hours after LPS 
exposure. The levels of IL -ip dramatically rose by six and twelve hours to 791 pg/mL IL- 
1P for both time points (extrapolated values).
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Figure 18: Effects of the PAF Receptor Antagonist, WEB2170, on Fold PAF-AH 
Induction and PAF-AH Standard Curve. A. MM6 cells were cultured in serum- 
containing media for twenty-four hours with 0.5 |xM PAF or 200 ng/mL LPS, alongside 
either 50 gM WEB2170 or 15 gM SB203580. WEB2170 was an effective PAF receptor 
antagonist and was also able to inhibit the LPS-induced PAF-AH mRNA upregulation. 
Administration of LPS, SB203580 and WEB2170 together decreased PAF-AH mRNA 
levels to half those of control levels. B. Real-Time PCR curves showing differences in 
PAF-AH mRNA levels for each noted experimental condition. The data reflect a value 
of two independent biological samples analyzed in triplicate; mean difference is 
significant at p<0.05. The single asterisk represents statistical significance between PAF
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and PAF + WEB2170 administration. The double asterisk represents statistical 
significance between LPS and LPS + SB203580 administration. The triple asterisk 
represents statistical significance between LPS + WEB2170 and LPS + WEB2170 + 
SB203580 administration. Error bars represented are +/- standard deviation.
By twenty-four hours, IL-ip protein levels fell to control levels with 169 pg/mL of IL-ip 
protein present. In control cells, IL -ip levels remained relatively constant with a slight 
trend of increasing IL-ip over the twenty-four hour incubation period (15-200 pg/mL).
3.9 TNF-a Induction in Response to LPS Treatment 
As mentioned previously, TNF-a is a cytokine involved in acute phase systemic 
inflammation. In order to investigate increases in TNF-a protein production as a result of 
LPS administration, MM6 cells were cultured as described in the previous section. As 
shown in Figure 20, control cells not receiving LPS produced very little TNF-a and 
levels detected ranged from 17 pg/mL (time 0) to 43 pg/mL (24-hours) Supemates from 
the LPS-induced cells showed a sharp increase by one-hour. TNF-a protein production 
reached a maximal 577 pg/mL. After six hours, TNF-a levels began fell to 413 pg/mL 
and 253 pg/mL by twelve and twenty-four hours respectively.
3.10 Phospho-p38a Induction in Response to LPS Treatment 
Phosphophorylated-p3 8 (p-p38a) is produced in the cell upon activation of the 
p38MAPK portion of the MAPK cascades. This portion of the MAPK cascade is 
activated upon exposure to inflammatory mediators, and various cellular stresses and this 
pathway helps to regulate cell differentiation and apoptosis. To determine if the 
p38MAPK pathway is indeed activated in MM6 cells, ELISAs against the p-p38a were
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preformed. (See Figure 21). As described above, MM6 cells were grown in serum- 
containing media for twenty-fours then switched to serum-free media.
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Figure 19: IL -ip  ELISA. A. MM6 cells were cultured in serum-free media in the 
presence of 500 ng/mL LPS and the conditioned media was collected twenty-four hours 
later to be used in ELISAs. IL-ip protein levels begin to increase by thirty-minutes of
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LPS exposure and levels rise substantially by six and twelve hours. Values at six and 
twelve hours are extrapolated due to the large induction in IL-ip protein levels at those 
time points. IL -ip protein levels begin to increase by three-hours in control conditions 
and continue to rise by twenty-four hours. B. Computer generated four-parameter logistic 
curve fit showing correlation. The data reflect a value o f two independent biological 
samples analyzed in duplicate; mean difference is significant at p<0.01. The single 
asterisk represents statistical difference between the six and twelve hour time points 
compared to the corresponding control time points. Error bars represented are +/- 
standard deviation.
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Figure 20; TNF-a ELISA. A. MM6 cells were cultured in serum-free media in the 
presence of 500 ng/mL LPS and the conditioned media was collected twenty-four hours 
later to be used in ELISAs. Incremental increases in TNF-a protein were observed, upon 
administration of 500 ng/mL LPS, with maximal protein levels present at six-hours. 
Subsequent to this time point, levels begin to fall steadily. Control levels remain 
relatively steady throughout the time course. B. Computer generated four-parameter 
logistic curve fit showing correlation. The data reflect a value of two independent 
biological samples analyzed in duplicate; mean difference is significant at p<.001. The 
single asterisk represents a statistical difference between the one through twenty-four 
hour time points compared to the corresponding control time points. Error bars 
represented are +!- standard deviation.
Cell pellets were resuspended in cell lysis buffer to give a density of 10  ̂cells/mL. Before 
use in ELISAs, a series o f two, six-fold dilutions were prepared. An analysis o f the p- 
p38a ELISA demonstrated a statistically significant increase in the amount o f p-p38a 
protein at one and three hours compared to controls. (1.3 ng p-p38a/ 10  ̂ cells vs. 1.0 ng 
p-p38a/ 10^; 1.1 ng p-p38a/ 10  ̂ vs. 1.4 ng p-p38a/ 10^) Subsequent to this time, p-p38a 
levels decrease to .78 ng p-p38a/10^ cells by twenty-four hours. Control levels o f p-p38a 
fluctuate between .99 and 1.4 ng p-p38a/10^ cells over the entire twenty-four hour time 
course.
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Figure 21: p-p38a ELISA. A. MM6 cells were cultured in serum-free media for twenty 
four hours in the presence of 500 ng/mL LPS. Cells were harvested, centrifuged and cell 
pellets were lysed in cell lysis buffer to give a density of 10  ̂ cells/mL to be used in 
ELISAs. A statistical difference in p-p38a protein levels is observed between the one and 
three hour time points. B. Computer generated four-parameter logistic curve fit showing 
correlation. The data reflect a value of two independent biological samples analyzed in 
duplicate; mean difference is significant at p<0.05. The single asterisk represents 
statistical difference between the one and three hour time points compared to the 
corresponding control time points. Error bars represented are +/- standard deviation.
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3.11 Reactive Oxygen Species Induced Upregulation o f  PAF-AH mRNA 
Because of the results depleted in Figures 10 and 11, we hypothesized that reactive 
oxygen species (ROS) may induce PAF aeetylhydrolase mRNA production. To 
investigate this possibility, 100 pM tert- butyl hydroperoxide (TBHP), an inducer of 
ROS, was administered to MM6 cells in serum-eontaining media for twenty-four hours. 
The cells were harvested, RNA isolated, reverse transcribed to eDNA and analyzed via 
Real-Time PCR. Real-Time PCR showed near control levels o f PAF aeetylhydrolase 
mRNA for the initial twelve hours; however, at twenty-four hours TBHP exposure 
produced a 2.5-fold increase in PAF. (See Figure 22).
3.12 Morphological Changes in MM6 cells in Response to Singly and Dually 
Administered Proinjlammatory Mediators 
While inducing inflammatory responses in MM6 cells, various morphological changes, 
specifically cell clumping, were observed during the incubation times. These 
morphological changes may have physiological relevance. Since infiltration from the 
vasculature to the injured tissues is a necessary action to mediate an inflammatory 
response, expression of various adhesion molecules may play a beneficial role in this 
regard. As shown in Figures 23A and 23B, the degree of cell clumping roughly parallels 
the fold induction of PAF-aeetylhydrolase mRNA levels in response to these mediators. 
LPS-treated MM6 cells showed the greatest extent in cell clumping compared to TNF-a 
and PAF alone. Dual administration o f proinflammatory mediators showed greater cell 
clumping compared to the singly administered proinflammatory mediators. LPS 4- TNF-a
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appeared to demonstrate the greatest degree of cell clumping followed by PAF + LPS and 
TNF-a + PAF.
TBHP Induction of PAF Aeetylhydrolase Expression
I
Hours
Figure 22: ROS induced Upregulation of PAF-AH mRNA. MM6 cells were cultured 
in serum-containing media in the presence of 100 pM tert- butyl hydroperoxide for 
twenty-four hours. Near control levels of PAF aeetylhydrolase mRNA induction are 
observed for the first twelve with a 2.5 fold increase in PAF aeetylhydrolase mRNA 
levels at twenty-four hours. The data reflect a value of two independent biological 
samples analyzed in triplicate; mean difference is significant at p<0.05. The single 
asterisk represents statistical significance from the control. Error bars represented are +/- 
standard deviation.
46
■IIIIIIIM
C o n t r o l
TNF-(/
47
B.
Control PAF + LPS
TNF-a + LPS
&  % : 4
TNF-a + PAF
Figure 23: Morphological Changes in MM6 Cells After Administration of Various 
Proinflammatory Mediators. A. Effects o f various proinflammatory mediators on the 
morphological changes in MM6 cells. B. Effects of dually administered proinflammatory 
mediators on MM6 cells. MM6 cells were incubated with the above listed 
proinflammatory mediators and combinations therein for twenty-four hours. LPS was 
administered at 200 ng/mL. PAF was administered at a concentration of 0.5pM. TNF-a 
was administered at a concentration of 10 ng/mL. The degree o f cell clumping for the 
singly and dually administer mediators roughly parallels the extent o f PAF 
aeetylhydrolase mRNA upregulation. Total magnification shown is at 50X.
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CHAPTER 4
DISCUSSION
4.1 Analysis o f  Results 
The goal of this study was to investigate PAF aeetylhydrolase expression in 
response to both TNF-a and PAF and elucidate any similarities or differences that this 
response may have with respect to the EPS-induced response. TNF-a and PAF are known 
inflammatory mediators; however, it was not known whether these mediators would be 
able to affect PAF aeetylhydrolase expression. In order to investigate this possibility, 
dose response experiments were performed. With increasing concentrations of LPS, PAF 
or TNF-a, MM6 cells were exposed to the various concentrations for twenty-four hours 
in serum-containing media and the level of PAF aeetylhydrolase mRNA was analyzed 
through Real-Time PCR experiments. Dose response experiments indeed showed the 
ability for both TNF-a and PAF (like LPS) to upregulate PAF aeetylhydrolase 
expression. (See Figures 7-9). LPS showed the greatest ability to induce PAF 
aeetylhydrolase mRNA levels followed by TNF-a and PAF. Increasing concentrations of 
both LPS and TNF-a resulted in increasing levels of PAF aeetylhydrolase mRNA. 
However, the PAF dose response did not appear dose dependent. For all concentrations 
of PAF administered, an approximately three-fold increase over PAF aeetylhydrolase 
levels was observed. This observation is most likely the result of the presence o f PAF 
aeetylhydrolase in the fetal bovine serum (FBS) that rapidly inactivates PAF. Thus, only
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a portion of PAF is available to bind the receptor and signal. The wide variation 
observed in PAF aeetylhydrolase expression levels (2-20-fold), for all presented dose 
responses, induced by the various mediators, demonstrates that the PAF aeetylhydrolase 
gene is highly regulated rather than “on or off.” This observation hints that varying levels 
of PAF aeetylhydrolase are induced contingent upon the degree of inflammation present 
in the host. Previous work by Howard et al. demonstrated upregulation o f PAF 
aeetylhydrolase in rats exposed to LPS (32). Furthermore, the increased expression was 
detected solely in Kupffer cells, the resident macrophages of the liver. We have 
successfully reproduced the in vivo macrophage response to LPS in our cultured MM6 
cells. Since PAF and TNF-a are capable o f inducing PAF aeetylhydrolase expression in 
the MM6 cells, this likely represents a physiologically relevant response that would be 
seen in vivo.
Our data in MM6 cells are in good agreement with that by Howard et al. that 
demonstrated maximal induction of PAF aeetylhydrolase mRNA and protein via in vivo 
LPS administration in the liver sinusoidal cells of rats at twenty-four hours (32) (42). 
Further, in our work, LPS, PAF and TNF-a were able to upregulate PAF aeetylhydrolase 
mRNA expression beginning at around 12-hours, with both TNF-a and LPS-indueed 
PAF aeetylhydrolase mRNA levels peaking at twenty-four hours. (See Figures 10-13). 
However, the PAF induced response continued to increase at both forty-eight and 
seventy-two hours. This time frame for PAF aeetylhydrolase induction agrees with what 
is seen in vivo (42). The LPS-indueed upregulation of PAF aeetylhydrolase mRNA is 
mediated by interaction of LPS with LPS binding protein (LBP) present in the serum. 
LPS and LBP form a complex which delivers the LPS to CD 14, a eell surfaee reeeptor.
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The new LPS-CD14 eomplex then interacts with a member of the toll-like receptor super 
family ealled TLR-4. The aetivation of TLR-4 initiates signaling through the MAPK 
cascades as shown in Figure 5 (31). Experiments were preformed to determine if  EBP is 
required for the EPS-induced expression of PAF aeetylhydrolase. In the presenee o f 10% 
FBS, and henee EBP, a 10-20 fold increase in PAF aeetylhydrolase expression was 
detected after the addition of EPS. Control eells not reeeiving EPS, demonstrated low 
constitutive levels o f PAF aeetylhydrolase mRNA as shown in Figure 10. In the absenee 
o f serum, PAF aeetylhydrolase levels also increased with time. Surprisingly, this inerease 
was deteeted in eells that did and did not reeeive EPS. (See Figure 11). This EPS- 
independent response was partieularly robust at forty-eight and seventy-two hours where 
an over thirty and sixty-fold inerease in PAF aeetylhydrolase mRNA levels was deteeted 
respeetively.
Beeause PAF aeetylhydrolase mRNA expression was indueed under the serum- 
free eonditions, regardless of EPS administration, we were unable to equivoeally 
determine if EBP is required for EPS signaling. However, no statistieally signifieant 
differenees were detected in the magnitude of induetion between EPS-treated and eontrol 
eells. This either represents the faet that EPS requires the presenee of EBP for signaling 
or that the EPS-independent induetion is so large that it is masking any solely EPS- 
mediated effeets.
MM6 eells eultured under serum-free eonditions begin to deteriorate in 
morphologieal appearance and viability beginning around twenty-four hours (Data not 
shown). By seventy-two hours, over 50% of the eell population is non-viable. Clearly, 
environmental stress indueed by eell starvation for prolonged periods, dramatieally
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induced PAF aeetylhydrolase mRNA expression. During times of environmental stress, 
ROS levels can increase dramatieally. Therefore, it is possible that the large extent of 
PAF aeetylhydrolase induetion in serum-free eonditions at forty-eight and seventy-two 
hours may be the result of generation of ROS. Kulisz et al. have shown that ROS inerease 
the amount of p-p38a (43). Thus, an induction in ROS may be responsible for the large 
increase in PAF aeetylhydrolase mRNA levels observed both at the forty-eight and 
seventy-two hour time points in serum-free media. To a slight extent, these ROS may 
also generate an uncontrolled production of PAF-like phospholipids that can also 
upregulate PAF aeetylhydrolase mRNA levels.
To investigate if ROS are capable o f inducing the PAF aeetylhydrolase message, 
we administered a ROS inducer, tert-huiy\ hydroperoxide (TBHP) at 100 pM. TBHB 
administration resulted in a 2.5-fold inerease in PAF aeetylhydrolase expression at 
twenty-four hours This result clearly demonstrated that ROS can indeed induce 
expression of PAF aeetylhydrolase. However, additional experiments are required to 
assay for induetion at the forty-eight and seventy-two hour time points. Further, the 2.5- 
fold induction upon 100 pM TBHP did not recapitulate the thirty and sixty-fold induetion 
observed at the forty-eight and seventy-hour time points for cultured MM6 eells in 
serum-free media. This may be due to insufficient production of ROS. Dose response 
experiments with TBHP may help determine the effective concentrations to recapitulate 
the serum-free RPMI result. Further, LPS is able to induce the formation of superoxide 
radicals in alveolar macrophages and other phagocytes as part of the immune system 
mechanism of killing pathogens (44). The faet that ROS are able to induce the expression
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of PAF aeetylhydrolase makes logical sense to hydrolyze any oxidized phospholipids that 
can be formed.
To elucidate any similarities in signaling between LPS, TNF-a, and PAF, the 
proinflammatory mediators were administered in various combinations. Administration 
of TNF-a and LPS together stimulated PAF aeetylhydrolase expression far greater than 
TNF-a or LPS alone. This observed effect was greater than what would be predicted from 
just an additive response. The synergism detected between TNF-a and LPS suggests 
TNF-a activates signaling pathways that influence the response to LPS (i.e. cross-talk). 
In contrast, the PAF aeetylhydrolase induction in response to LPS plus PAF and TNF-a 
plus PAF was approximately additive. This observation suggests the activation of parallel 
but independent pathways that result in stimulated PAF aeetylhydrolase expression. 
Because of these observations, and the importance of the MAPK pathways in 
inflammatory responses, the roles of the various portions o f the MAPK pathways were 
investigated.
Examination of the MAPK pathways that were important in the EPS-mediated 
upregulation of PAF aeetylhydrolase showed predominant signaling through the p38 
portion of the MAPK pathway marked by 50% inhibition from SB203580. (Figure 15). 
For TNF-a- treated MM6 cells, inhibition of the p38MAPK pathway showed a 20% 
decrease in PAF aeetylhydrolase induction that was found not to be statistically 
significant. This indicates only a minor role for the p38MAPK pathway in TNF-a 
signaling. Similar to the TNF-a response, the PAF-induced induction of PAF 
aeetylhydrolase was also decreased by approximately 20% in the presence o f SB203580; 
however, this decrease was not statistically significant (Figure 17). These data show a
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significant difference in the signaling between LPS compared to TNF-a/PAF signaling. 
In these presented experiments, inhibition with SP600125, an inhibitor of the INK 
portion of the pathway was not investigated—although the INK inhibitor does not alter 
the LPS-indueed expression (data not shown). To further elucidate the predominant 
signaling pathways involved in TNF-a and PAF signaling with the dual administration of 
inhibitors must be performed
Interestingly, inhibition of the ERKl/2 MAPK showed a 50% increase in PAF 
aeetylhydrolase production over the induction elicited by the pro-inflammatory mediators 
alone (LPS, TNF-a, and PAF). (See Figures 16 and 17). Additionally, inhibition of 
ERKl/2 by itself resulted in a small but significant increase in PAF aeetylhydrolase 
levels. This result may be explained by the fact that the MAPK pathways play diverse 
roles in signaling that regulate cell proliferation, differentiation, gene expression and cell 
survival (45). Specifically, the ERKl/2 portion of the MAPK pathway regulates cell 
differentiation and proliferation. Thus, inhibition of this pathway may impose a further 
stress on the cell which results in slight activation of p38MAPK and thus increased PAF 
aeetylhydrolase levels.
Stafforini et al. have shown that EPS-induced PAF aeetylhydrolase induction is 
solely mediated through the p38 portion of the MAPK pathway in THP1/CD14 cells (40). 
Our work in MM6 cells showed 5(3% inhibition of PAF aeetylhydrolase mRNA induction 
upon exposure to SB203580—the p38MAPK inhibitor. Interestingly, Howard et al. 
demonstrated the PAF receptor antagonist, WEB2170, was able to downregulate the in 
vivo LPS-indueed upregulation of PAF aeetylhydrolase in rats by 50% (36). Thus, these 
separate observations prompted experiments to détermine the effects of dually
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administered SB203580 and WEB2170. The PAF receptor antagonist, WEB2170, was 
administered prior to stimulation with LPS or PAF. As expected, WEB2170 is an 
effective PAF receptor antagonist and able to inhibit the PAF-induced response. LPS- 
indueed upregulation o f PAF aeetylhydrolase mRNA was inhibited by approximately 
50% by the PAF receptor antagonist. Importantly, dual administration o f SB203580 in 
conjunction with WEB2170 completely abolished PAF aeetylhydrolase induction. Our 
data strongly support our contention that the remaining LPS-indueed PAF 
aeetylhydrolase mRNA levels present after SB203580 administration are the result of 
increased PAF production and signaling instigated by LPS administration. Our findings 
are in contrast with the work of Stafforini et al. in that the LPS-mediated upregulation of 
PAF aeetylhydrolase is solely p38MAPK dependent. Although not examined, it would be 
interesting to determine if the effects of TNF-a are also partly mediated via PAF 
biosynthesis and PAF-receptor activation. TNF-a is capable of stimulating PAF synthesis 
in monocytes (46).
In order to gain a more thorough understanding o f the inflammatory response in 
MM6 cells, ELISAs for IL-lp, TNF-a and p-p38a were performed. (See Figures 19-21). 
hese experiments were performed in serum-free media to assay for the secreted 
cytokines. Because o f the absence of serum in the media and thus a lack of LBP, a 500 
ng/mL LPS dose was administered to ensure signaling through TLR-4. Cell lysates and 
conditioned media exposed to LPS were harvested and used in various ELISAs. The 
ELISAs showed the ability of MM6 cells to mount an inflammatory response to LPS and 
secrete various cytokines such as TNF-a and IL-ip. Because the PAF receptor 
antagonists partly inhibited the LPS-indueed upregulation of PAF aeetylhydrolase, we
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concluded that the proinflammatory mediator PAF is .also being produced. Maximal 
induction of IL-ip or TNF-a protein occurred between six and twelve hours. In our 
experiments examining PAF aeetylhydrolase mRNA, maximal levels were observed by 
twenty-four hours (Figures 10, 12 and 13). This delayed responsiveness in PAF 
aeetylhydrolase induction most likely reflects the need to control and limit PAF and PAF- 
like mediator production at this later stage. In other words, initial PAF production is a 
beneficial response, but left unchecked, can lead to unwanted effects. The induction of 
PAF aeetylhydrolase at twenty-four hours most likely serves to limit the damage that can 
occur during an inflammatory response and helps promote recovery of the host.
Statistically significant differences in p-p38a by one hour and three hours show 
that LPS is indeed signaling through the p38 portion of the MAPK pathway— further 
advancing the hypothesis that LPS signals at least in part through p38MAPK. However, 
at time points other than one and three hours, no statistical differences were seen. A 
repeat of this ELISA is necessary in order to clarify this result and gain a more thorough 
understanding.
There are numerous signaling pathways that are linked to the PAF receptor 
activation and this may explain the many PAF-induced biological responses of various 
cell types. PAF stimulates the expression of adhesion molecules and various cell surface 
receptors, when the PAF receptor is stimulated (47,48). In our experiments, 
administration o f LPS, PAF and TNF-a and combinations thereof showed marked 
morphological changes in the MM6 cells, specifically cell clumping. (See Figures 23A 
and 23B). This observation may have physiological relevance. Monocytes express the 
ligand for P selectin, P selectin glycoprotein ligand-1, which aids in adhesive interactions
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with both endothelial cells and platelets (47). Such expression is relevant since 
infiltration from the vasculature into the tissue is necessary in an inflammatory response 
to rid the infected area of invading microorganisms or necrotic tissue. Exactly how LPS, 
TNF-a and PAF are producing MM6 cell clumping remains to be demonstrated.
4.2 Conclusions and further Work
This research has shown the various signaling pathways that are important in 
inducing the upregulation of the plasma form of PAF aeetylhydrolase. We have 
demonstrated that in addition to LPS, TNF-a and PAF are able to upregulate PAF 
aeetylhydrolase expression with LPS being the most potent inducer followed by TNF-a 
and PAF. We have also demonstrated that 50% of the observed LPS-indueed 
upregulation of PAF aeetylhydrolase is the result of PAF signaling through its reeeptor. 
Though the LPS-indueed response is partly p38MAPK dependent, the induction observed 
for both TNF-a and PAF is not. The TNF-a and PAF-induced induction of PAF 
aeetylhydrolase levels may be the result of increased PAF synthesis upon administration 
of these mediators or signaling through a separate pathway(s). In these studies, the role of 
the JNK portion of the MAPK pathway was not investigated. Further work is necessary 
to elucidate the role that this pathway may have with TNF-a or PAF signaling.
Additionally, the 50% induction in PAF aeetylhydrolase mRNA levels (relative to 
the inflammatory mediator administered) after administration of the ERKl/2 inhibitor 
requires further investigation. Performing ELISAs, speeifie for p-p38a protein, and 
assays for ROS will help answer the question whether cellular stresses, increased 
activation of p38MAPK, or both occur in the presenee of PD98059. Work by Kulisz et al.
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supports our hypothesis that eellular stresses, speeifieally ROS, ean inerease p38MAPK 
aetivation (43). Our work with TBHP has shown the ability of ROS to induee PAF 
aeetylhydrolase levels. Whether this is p38MAPK-dependent in MM6 eells still requires 
further elueidation.
In eonelusion, we have demonstrated that LPS, TNF-a, and PAF are able to 
induee PAF aeetylhydrolase expression and have gained a greater understanding in 
regulation of PAF aeetylhydrolase expression. The inereases in PAF aeetylhydrolase 
levels, in response to numerous mediators, likely represent the physiologieal requirement 
to eurb the progression of the inflammatory response and maintain the viability o f the 
host. Thus, the work presented here furthers our knowledge concerning the roles played 
by the plasma PAF aeetylhydrolase in the inflammatory process.
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